The Expert Guide to Beating Heart Disease What You Absolutely Must Know by Krumholz

REFERENCES 233 teriosclerosis, Thrombosis and Vascular Biology, 2001, Vol. 21, Iss. 6, 1084–1089.Evaluation of certain food additives and contaminants. Forty-sixth report of the Joint FAO/WHO Expert Committee on Food Ad- ditives. World Health Organization Technical Reporting Ser- vice, 1997, Vol. 868, 1–69.Facts about the DASH diet. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, 1998.Foreyt, J. P., and W. S. Poston. Consensus view on the role of di- etary fat and obesity. American Journal of Medicine, 2002, Vol. 113, Suppl. 9B, 60S–62S.Geleijnse, J. M., et al. Tea flavonoids may protect against athero- sclerosis: the Rotterdam Study. Archives of Internal Medicine, 1999, Vol. 159, Iss. 18, 2170–2174.He, K., et al. Fish consumption and risk of stroke in men. Journal of the American Medical Association, 2002, Vol. 288, Iss. 24, 3130–3136.Hites, R. A., et al. Global assessment of organic contaminants in farmed salmon. Science, 2004, Vol. 303, Iss. 5655, 226–229.Holub, B. J. Clinical nutrition: 4. Omega-3 fatty acids in cardiovas- cular care. Canadian Medical Association Journal, 2002, Vol. 166, Iss. 5, 608–615.Hu, F. B., and W. C. Willett. Optimal diets for prevention of coro- nary heart disease. Journal of the American Medical Association, 2002, Vol. 288, Iss. 20, 2569–2578.Hu, F. B., et al. Fish and omega-3 fatty acid intake and risk of coro- nary heart disease in women. Journal of the American Medical Association, 2002, Vol. 287, Iss. 14, 1815–1821.Hu, F. B., et al. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. British Med- ical Journal, 1998, Vol. 317, Iss. 7169, 1341–1345.Jenkins, D. J., et al. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipopro- teins, lipoprotein(a), homocysteine, and pulmonary nitric oxide. Circulation, 2002, Vol. 106, Iss. 11, 1327–1332.

234 REFERENCESJiang, R., et al. Nut and peanut butter consumption and risk of type 2 diabetes in women. Journal of the American Medical As- sociation, 2002, Vol. 288, Iss. 20, 2554–2560.Joshipura K. J., et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Annals of Internal Medicine, 2001, Vol. 134, Iss. 12, 1106–1114.Krauss, R. M., et al. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Com- mittee of the American Heart Association. Circulation, 2000, Vol. 102, Iss. 18, 2284–2299.Kris-Etherton, P. M., W. S. Harris, and L. J. Appel. Fish consump- tion, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 2002, Vol. 106, Iss. 21, 2747–2757.Liu, S., et al. Whole-grain consumption and risk of coronary heart disease: results from the Nurses’ Health Study. American Jour- nal of Clinical Nutrition, 1999, Vol. 70, Iss. 3, 412–419.Marchioli, R., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time- course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation, 2002, Vol. 105, Iss. 16, 1897–1903.Nielsen, S. J., and B. M. Popkin. Patterns and trends in food por- tion sizes, 1977–1998. Journal of the American Medical Associa- tion, 2003, Vol. 289, Iss. 4, 450–453.Ornish, D., et al. Intensive lifestyle changes for reversal of coronary heart disease. Journal of the American Medical Association, 1998, Vol. 280, Iss. 23, 2001–2007.Pereira, M. A., et al. Dietary fiber and risk of coronary heart dis- ease. Archives of Internal Medicine, 2004, Vol. 164, Iss. 4, 370– 376.Sesso, H. D., et al. Coffee and tea intake and the risk of myocardial infarction. American Journal of Epidemiology, 1999, Vol. 149, Iss. 2, 162–167.Stevinson, C., M. H. Pittler, and E. Ernst. Garlic for treating hyper- cholesterolemia. A meta-analysis of randomized clinical trials. Annals of Internal Medicine, 2000, Vol. 133, Iss. 6, 420–429.

REFERENCES 235Titan, S. M., et al. Frequency of eating and concentrations of serum cholesterol in the Norfolk population of the European Prospective Investigation into Cancer (EPIC-Norfolk): cross sectional study. British Medical Journal, 2001, Vol. 323, Iss. 7324, 1286–1288.Willett, W. C., and M. J. Stampfer. Rebuilding the food pyramid. Scientific American, 2003, Vol. 288, Iss. 1, 64–71.Wylie-Rosett, J. Fat substitutes and health: an advisory from the Nutrition Committee of the American Heart Association. Cir- culation, 2002, Vol. 105, Iss. 23, 2800–2804.Consuming AlcoholAlbert, M. A., R. J. Glynn, and P. M. Ridker. Alcohol consumption and plasma concentration of C-reactive protein. Circulation, 2003, Vol. 107, Iss. 3, 443–447.Berger, K., et al. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. New England Journal of Medicine, 1999, Vol. 341, Iss. 21, 1557–1564.Corder, R., et al. Endothelin-1 synthesis reduced by red wine. Na- ture, 2001, Vol. 414, Iss. 6866, 863–864.Gronbaek, M., et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Annals of Inter- nal Medicine, 2000, Vol. 133, Iss. 6, 411–419.Miyagi, Y., K. Miwa, and H. Inoue. Inhibition of human low- density lipoprotein oxidation by flavonoids in red wine and grape juice. American Journal of Cardiology, 1997, Vol. 80, Iss. 12, 1627–1631.Mukamal, K. J., et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. New England Jour- nal of Medicine, 2003, Vol. 348, Iss. 2, 109–118.Naimi, T. S., et al. Binge drinking among US adults. Journal of the American Medical Association, 2003, Vol. 289, Iss. 1, 70–75.Reynolds, K., et al. Alcohol consumption and risk of stroke: a meta-analysis. Journal of the American Medical Association, 2003, Vol. 289, Iss. 5, 579–588.Rimm, E. B., et al. Moderate alcohol intake and lower risk of coro-

236 REFERENCES nary heart disease: meta-analysis of effects on lipids and haemostatic factors. British Medical Journal, 1999, Vol. 319, Iss. 7224, 1523–1528.Stampfer, M., and E. Rimm. Why heart disease mortality is low in France. Commentary: alcohol and other dietary factors may be important. British Medical Journal, 1999, Vol. 318, Iss. 7196, 1476–1477.Walsh, C. R., et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Annals of Internal Medicine, 2002, Vol. 136, Iss. 3, 181–191.Wannamethee, S. G., and A. G. Shaper. Taking up regular drinking in middle age: effect on major coronary heart disease events and mortality. Heart, 2002, Vol. 87, Iss. 1, 32–36.Taking Vitamins and Other SupplementsAscherio, A., et al. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Annals of Internal Medicine, 1999, Vol. 130, Iss. 12, 963–970.Bostom, A. G., et al. Power Shortage: clinical trials testing the “ho- mocysteine hypothesis” against a background of folic acid- fortified cereal grain flour. Annals of Internal Medicine, 2001, Vol. 135, Iss. 2, 133–137.Brown, B. G., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine, 2001, Vol. 345, Iss. 22, 1583– 1592.Corrigan, J. J., Jr., and L. L. Ulfers. Effect of vitamin E on pro- thrombin levels in warfarin-induced vitamin K deficiency. American Journal of Clinical Nutrition, 1981, Vol. 34, Iss. 9, 1701–1705.Dietary supplements; vitamin sales rose 50% since 1994, report says. Chicago Tribune 1999, January 29, 7.Jacques, P. F., et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. New England Journal of Medicine, 1999, Vol. 340, Iss. 19, 1449–1454.

REFERENCES 237Kim, J. M., and R. H. White. Effect of vitamin E on the anticoagu- lant response to warfarin. American Journal of Cardiology, 1996, Vol. 77, Iss. 7, 545–546.Kolata, G. Vitamins: more may be too many. New York Times 2003, April 29, 1.Mayer, C. E. Rite Aid, GNC form an alliance; nutrition outlets coming to drugstores. Washington Post, 1999, January 8, F03.MRC/BHF Heart Protection Study of antioxidant vitamin supple- mentation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, Vol. 360, Iss. 9326, 23–33.Nutrition Examination Survey (1991–1994): population reference ranges and contribution of vitamin status to high serum con- centrations. Annals of Internal Medicine, 1999, Vol. 131, Iss. 5, 331–339.Pruthi, S., T. G. Allison, and D. D. Hensrud. Vitamin E supple- mentation in the prevention of coronary heart disease. Mayo Clinic Proceedings, 2001, Vol. 76, Iss. 11, 1131–1136.Schnyder, G., et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. Journal of the American Medical Association, 2002, Vol. 288, Iss. 8, 973–979.Selhub, J., et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991–1994): population reference ranges and contribution of vitamin status to high serum concentrations. Annals of Internal Medicine, 1999, Vol. 131, Iss. 5, 331–339.Willett, W. C., and M. J. Stampfer. Clinical practice. What vita- mins should I be taking, doctor? New England Journal of Medi- cine, 2001, Vol. 345, Iss. 25, 1819–1824.Yusuf, S., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medi- cine, 2000, Vol. 342, Iss. 3, 154–160.

238 REFERENCESReducing StressBenson, H., J. F. Beary, and M. P. Carol. The relaxation response. Psychiatry, 1974, Vol. 37, Iss. 1, 37–46.Benson, H., J. B. Kotch, and K. D. Crassweller. Stress and hyper- tension: interrelations and management. Cardiovascular Clinics, 1978, Vol. 9, Iss. 1, 113–124.Bernardi, L., et al. Effect of rosary prayer and yoga mantras on au- tonomic cardiovascular rhythms: comparative study. British Med- ical Journal, 2001, Vol. 323, Iss. 1, 1446–1449.Blumenthal, J. A., et al. Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. American Journal of Cardiology, 2002, Vol. 89, Iss. 2, 164–168.Coronary-prone behavior and coronary heart disease: a critical re- view. The Review Panel on Coronary-prone Behavior and Coro- nary Heart Disease. Circulation, 1981, Vol. 63, Iss. 6, 1199– 1215.Esch, T., et al. Stress in cardiovascular diseases. Medical Science Monitor, 2002, Vol. 8, Iss. 5, RA93–RA101.Hemingway, H., and M. Marmot. Evidence based cardiology: psy- chosocial factors in the aetiology and prognosis of coronary heart disease. Systematic review of prospective cohort studies. British Medical Journal, 1999, Vol. 318, Iss. 7196, 1460–1467.Johnston, D. W., D. G. Cook, and A. G. Shaper. Type A behaviour and ischaemic heart disease in middle aged British men. British Medical Journal (Clinical Research Edition), 1987, Vol. 295, Iss. 6590, 86–89.Kaplan, G. A., and J. E. Keil. Socioeconomic factors and cardiovas- cular disease: a review of the literature. Circulation, 1993, Vol. 88, Iss. 4 Pt. 1, 1973–1998.Kario, K., et al. Factors associated with the occurrence and magni- tude of earthquake-induced increases in blood pressure. Ameri- can Journal of Medicine, 2001, Vol. 111, Iss. 5, 379–384.Kubzansky, L. D., et al. Anxiety and coronary heart disease: a syn- thesis of epidemiological, psychological, and experimental evi- dence. Annals of Behavioral Medicine, 1998, Vol. 20, Iss. 2, 47–58.

REFERENCES 239Leor, J., W. K. Poole, and R. A. Kloner. Sudden cardiac death trig- gered by an earthquake. New England Journal of Medicine, 1996, Vol. 334, Iss. 7, 413–419.Parati, G., et al. Cardiovascular effects of an earthquake: direct ev- idence by ambulatory blood pressure monitoring. Hypertension, 2001, Vol. 38, Iss. 5, 1093–1095.van Montfrans, G. A., et al. Relaxation therapy and continuous am- bulatory blood pressure in mild hypertension: a controlled study. British Medical Journal, 1990, Vol. 300, Iss. 6736, 1368–1372.Using Hormone TherapyAnderson, G. L., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association, 2004, Vol. 291, Iss. 14, 1701– 1712.Grady, D., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replace- ment Study follow-up (HERS II). Journal of the American Med- ical Association, 2002, Vol. 288, Iss. 1, 49–57.Grady, D. Postmenopausal hormones—therapy for symptoms only. New England Journal of Medicine, 2003, Vol. 348, Iss. 19, 1835–1837.Grodstein, F., J. E. Manson, and M. J. Stampfer. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study. A prospective, observational study. Annals of Internal Medicine, 2001, Vol. 135, Iss. 1, 1–8.Hays, J., et al. Effects of estrogen plus progestin on health-related quality of life. New England Journal of Medicine, 2003, Vol. 348, Iss. 19, 1839–1854.Hodis, H. N., et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 2001, Vol. 135, Iss. 11, 939–953.Hulley, S., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Re-

240 REFERENCES placement Study follow-up (HERS II). Journal of the American Medical Association, 2002, Vol. 288, Iss. 1, 58–66.Hulley, S., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post- menopausal women. Heart and Estrogen/progestin Replace- ment Study (HERS) Research Group. Journal of the American Medical Association, 1998, Vol. 280, Iss. 7, 605–613.Humphrey, L. L., B. K. Chan, and H. C. Sox. Postmenopausal hor- mone replacement therapy and the primary prevention of car- diovascular disease. Annals of Internal Medicine, 2002, Vol. 137, Iss. 4, 273–284.Koh, K. K., et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation, 2002, Vol. 105, Iss. 13, 1531–1533.Manson, J. E., and K. A. Martin. Clinical practice. Postmenopausal hormone-replacement therapy. New England Journal of Medi- cine, 2001, Vol. 345, Iss. 1, 34–40.Miller, J., B. K. Chan, and H. D. Nelson. Postmenopausal estrogen replacement and risk for venous thromboembolism: a system- atic review and meta-analysis for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2002, Vol. 136, Iss. 9, 680–690.Mosca, L., et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 2001, Vol. 104, Iss. 4, 499–503.Nelson, H. D. Assessing benefits and harms of hormone replace- ment therapy: clinical applications. Journal of the American Medical Association, 2002, Vol. 288, Iss. 7, 882–884.Nelson, H. D., et al. Postmenopausal hormone replacement ther- apy: scientific review. Journal of the American Medical Associa- tion, 2002, Vol. 288, Iss. 7, 872–881.Rossouw, J. E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. Journal

REFERENCES 241 of the American Medical Association, 2002, Vol. 288, Iss. 3, 321–333.Viscoli, C. M., et al. A clinical trial of estrogen-replacement ther- apy after ischemic stroke. New England Journal of Medicine, 2001, Vol. 345, Iss. 17, 1243–1249.Vittinghoff, E., et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Annals of Internal Medicine, 2003, Vol. 138, Iss. 2, 81–89.Chapter 4. Research and Emerging TherapiesAlbert, M. A., et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Journal of the American Medical Association, 2001, Vol. 286, Iss. 1, 64–70.Bartlett, C., J. Sterne, and M. Egger. What is newsworthy? Longi- tudinal study of the reporting of medical research in two British newspapers. British Medical Journal, 2002, Vol. 325, Iss. 7355, 81–84.Collins, R. Heart protection study finds simvastatin reduces vascu- lar risk in a wide range of high-risk patients. American Journal of Managed Care, 2002, Suppl., 6.Freedman, S. B., and J. M. Isner. Therapeutic angiogenesis for coronary artery disease. Annals of Internal Medicine, 2002, Vol. 136, Iss. 1, 54–71.Gregoratos, G., et al. ACC/AHA guidelines for implantation of car- diac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Journal of the American College of Cardiology, 1998, Vol. 31, Iss. 5, 1175–1209.Grines, C. L., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 2002, Vol. 105, Iss. 11, 1291–1297.

242 REFERENCESHerrington, D. M., et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replace- ment Study (HERS). Circulation, 2002, Vol. 105, Iss. 25, 2962–2967.Jenkins, N. P., B. D. Prendergast, and M. Thomas. Drug eluting coronary stents. British Medical Journal, 2002, Vol. 325, Iss. 7376, 1315–1316.Morice, M. C., et al. A randomized comparison of a sirolimus- eluting stent with a standard stent for coronary revasculariza- tion. New England Journal of Medicine, 2002, Vol. 346, Iss. 23, 1773–1780.Moss. A. J., et al. Prophylactic implantation of a defibrillator in pa- tients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine, 2002, Vol. 346, Iss. 12, 877– 883.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, Vol. 360, Iss. 9326, 7–22.Pearson, T. A., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Dis- ease Control and Prevention and the American Heart Associa- tion. Circulation, 2003, Vol. 107, Iss. 3, 499–511.Ray, J. G., et al. Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine, 2001, Vol. 161, Iss. 11, 1405–1410.Ridker, P. M., et al. Comparison of C-reactive protein and low- density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine, 2002, Vol. 347, Iss. 20, 1557–1565.Ross, R. Atherosclerosis—an inflammatory disease. New England Journal of Medicine, 1999, Vol. 340, Iss. 2, 115–126.Waksman, R., et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised con- trolled trial. Lancet, 2002, Vol. 359, Iss. 9306, 551–557.

REFERENCES 243Chapter 5. Staying Well and PreparedBridges, C. B., et al. Prevention and control of influenza. Recom- mendations of the Advisory Committee on Immunization Prac- tices (ACIP). Morbidity and Mortality Weekly Report, 2002, Vol. 51, Iss. RR03, 1–31.Bristow, M. R., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine, 2002, Vol. 350, Iss. 21, 2140–2150.Bush, D. E., et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. American Jour- nal of Cardiology, 2001, Vol. 88, Iss. 4, 337–341.Frasure-Smith, N., F. Lesperance, and M. Talajic. Depression fol- lowing myocardial infarction. Impact on six-month survival. Journal of the American Medical Association, 1993, Vol. 270, Iss. 15, 1819–1825.Glassman, A. H., and P. A. Shapiro. Depression and the course of coronary artery disease. American Journal of Psychiatry, 1998, Vol. 155, Iss. 1, 4–11.Glassman, A. H., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. Journal of the Amer- ican Medical Association, 2002, Vol. 288, Iss. 6, 701–709.Guck, T. P., et al. Assessment and treatment of depression follow- ing myocardial infarction. American Family Physician, 2001, Vol. 64, Iss. 4, 641–648.Keller, M. B., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combi- nation for the treatment of chronic depression. New England Journal of Medicine, 2000, Vol. 342, Iss. 20, 1462–1470.Lavallee, P., et al. Association between influenza vaccination and reduced risk of brain infarction. Stroke, 2002, Vol. 33, Iss. 2, 513–518.Mendes de Leon, C. F., et al. Depression and risk of coronary heart disease in elderly men and women: New Haven EPESE, 1982–1991. Established Populations for the Epidemiologic

244 REFERENCES Studies of the Elderly. Archives of Internal Medicine, 1998, Vol. 158, Iss. 21, 2341–2348.Musselman, D. L., D. L. Evans, and C. B. Nemeroff. The relation- ship of depression to cardiovascular disease: epidemiology, biol- ogy, and treatment. Archives of General Psychiatry, 1998, Vol. 55, Iss. 7, 580–592.Naghavi, M., et al. Association of influenza vaccination and re- duced risk of recurrent myocardial infarction. Circulation, 2000, Vol. 102, Iss. 25, 3039–3045.Nissen, S. E., et al. Effect of recombinant ApoA-I Milano on coro- nary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Journal of the American Medical Association, 2003, Vol. 290, Iss. 17, 2292–2300.Penninx, B. W., et al. Depression and cardiac mortality: results from a community-based longitudinal study. Archives of General Psychiatry, 2001, Vol. 58, Iss. 3, 221–227.Reynolds, C. F., 3rd, et al. Nortriptyline and interpersonal psy- chotherapy as maintenance therapies for recurrent major de- pression: a randomized controlled trial in patients older than 59 years. Journal of the American Medical Association, 1999, Vol. 281, Iss. 1, 39–45.Rimm, E. B., et al. Moderate alcohol intake and lower risk of coro- nary heart disease: meta-analysis of effects on lipids and haemostatic factors. British Medical Journal, 1999, Vol. 319, Iss. 7224, 1523–1528.Schulz, R., et al. Association between depression and mortality in older adults: the Cardiovascular Health Study. Archives of Inter- nal Medicine, 2000, Vol. 160, Iss. 12, 1761–1768.Thase, M. E., et al. Treatment of major depression with psy- chotherapy or psychotherapy-pharmacotherapy combinations. Archives of General Psychiatry, 1997, Vol. 54, Iss. 11, 1009– 1015.

REFERENCES 245AppendicesAggarwal, A., and P. A. Ades. Interactions of herbal remedies with prescription cardiovascular medications. Coronary Artery Dis- ease, 2001, Vol. 12, Iss. 7, 581–584.Ameer, B., and R. A. Weintraub. Drug interactions with grapefruit juice. Clinical Pharmacokinetics, 1997, Vol. 33, Iss. 2, 103–121.Ament, P. W., J. G. Bertolino, and J. L. Liszewski. Clinically signif- icant drug interactions. American Family Physician, 2000, Vol. 61, Iss. 6, 1745–1754.Birkmeyer, J. D., et al. Hospital volume and surgical mortality in the United States. New England Journal of Medicine, 2002, Vol. 346, Iss. 15, 1128–1137.Cheitlin, M. D., et al. ACC/AHA guidelines for the clinical appli- cation of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Associa- tion Task Force on Practice Guidelines (Committee on Clini- cal Application of Echocardiography). Developed in collabo- ration with the American Society of Echocardiography. Journal of the American College of Cardiology, 1997, Vol. 29, Iss. 4, 862–879.Crawford, M. H., et al. ACC/AHA guidelines for ambulatory elec- trocardiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Circulation, 1999, Vol. 100, Iss. 8, 886–893.Eagle, K. A., et al. ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations. A re- port of the American College of Cardiology/American Heart As- sociation Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation, 1999, Vol. 100, Iss. 13, 1464–1480.Gibbons, R. J., et al. ACC/AHA guidelines for exercise testing: ex- ecutive summary. A report of the American College of Cardiol- ogy/American Heart Association Task Force on Practice

246 REFERENCES Guidelines (Committee on Exercise Testing). Circulation, 1997, Vol. 96, Iss. 1, 345–354.Hirshfeld, J. W., Jr., S. G. Ellis, and D. P. Faxon. Recommenda- tions for the assessment and maintenance of proficiency in coronary interventional procedures: statement of the American College of Cardiology. Journal of the American College of Cardi- ology, 1998, Vol. 31, Iss. 3, 722–743.Johnson, M. D., G. Newkirk, and J. R. White, Jr. Clinically signifi- cant drug interactions. Postgraduate Medicine, 1999, Vol. 105, Iss. 2, 193–195, 205–206.Kane, G. C., and J. J. Lipsky. Drug-grapefruit juice interactions. Mayo Clinic Proceedings, 2000, Vol. 75, Iss. 9, 933–942.O’Rourke, R. A., et al. American College of Cardiology/American Heart Association expert consensus document on electron- beam computed tomography for the diagnosis and prognosis of coronary artery disease. Journal of the American College of Car- diology, 2000, Vol. 36, Iss. 1, 326–340.Ritchie, J. L., et al. Guidelines for clinical use of cardiac radionu- clide imaging. Report of the American College of Cardiology/ American Heart Association Task Force on Assessment of Diag- nostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. Journal of the Ameri- can College of Cardiology, 1995, Vol. 25, Iss. 2, 521–547.Scanlon, P. J., et al. ACC/AHA guidelines for coronary angiogra- phy: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation, 1999, Vol. 99, Iss. 17, 2345–2357.Schlant, R. C., et al. Guidelines for electrocardiography. A report of the American College of Cardiology/American Heart Associa- tion Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Electrocardiogra- phy). Circulation, 1992, Vol. 85, Iss. 3, 1221–1228.

REFERENCES 247Smith, S. C., Jr., et al. ACC/AHA guidelines for percutaneous coro- nary intervention (revision of the 1993 PTCA guidelines)— executive summary. A report of the American College of Cardi- ology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Per- cutaneous Transluminal Coronary Angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation, 2001, Vol. 103, Iss. 24, 3019–3041.Smith, S. C., Jr., et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a state- ment for healthcare professionals from the American Heart As- sociation and the American College of Cardiology. Circulation, 2001, Vol. 104, Iss. 13, 1577–1579.Spertus, J. A., et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. Journal of the American College of Cardiology, 1995, Vol. 25, Iss. 2, 333–341.



INDEXAccupril, 101 AHA. See American HeartAcebutolol, 97 AssociationACE (angiotensin-converting Alcohol, 124–26 enzyme) inhibitors, 88, benefits of, in moderation, 125 100–103 blood pressure and, 18 commonly used, and brand names, 101 Aldosterone blockers, 104 defined, 201 Almonds, 120 diuretics versus, 19 Alpha-glucosidases inhibitors, 74 drug interactions, 183 Altace, 101 frequently asked questions, ALT (alanine aminotransferase) 102–3 recommended guidelines, 102 blood tests, 37 risks and benefits, 102 Alzheimer’s disease side effects, 21, 102Aceon, 101 calorie restriction and, 124Acetylsalicylic acid, 89 statins and, 35Action plan. See Key strategies Ambulatory blood pressureAcupuncture, 83Addictions. See Alcohol; Smoking monitoring (ABPM), 25Adrenaline, nicotine and, 78 American Cancer Society, 83Advance directives, 150–52 American College of CardiologyAerobic exercise, 42, 44–45, 46, 59African-Americans (ACC), xii, 9, 61, 201 glucose tests and, 68 American Diabetes Association hypertension and, 24Age, as risk factor, 6, 7 (ADA), 68, 71, 72, 199Aging, calorie restriction and, 124. American Heart Association See also Elderly, theAgriculture, U.S. Department of (AHA), xii, 201 (USDA), 110, 111 alcohol and, 126 aspirin guidelines, 90, 91 dietary guidelines, 56, 111 emerging therapies, 137 exercise guidelines, 42, 46 fish servings, 116 hormone therapy, 132 smoking and, 78

250 INDEXAmerican Heart Association Arrhythmia, defined, 202. See also (continued) Irregular heartbeat soy foods and, 122 Arteries, 1–2, 4, 30–31, 203 statins and, 37 Artificial sweeteners, 71 Web site, 199 Aspartate aminotransferase (AST)Angina, 2, 3, 4, 144 defined, 201 blood tests, 37 Seattle Angina Questionnaire, Aspirin, 88–94 144, 177–80 C-reactive protein and, 141–42 stable, defined, 205 drug interactions, 182 unstable, defined, 206 frequently asked questions,Angiograms, 6, 195–96Angioplasty, 139, 196–97, 201 92–94Angiotensin-converting enzyme for post–heart attacks, 103–5 recommended guidelines, 90, inhibitors. See ACE inhibitorsAngiotensin II, 100 92–93Angiotensin II receptor blockers. side effects, 90–91 who should avoid, 91 See ARBs AST (aspartate aminotransferase)Antibiotics, drug interactions, blood tests, 37 182–86 Atacand, 103Anticoagulants (blood thinners), Atenolol, 97, 183 Atherosclerosis, 2, 4, 70, 202 88–96. See also Aspirin Atkins diet, 63, 65 defined, 202 Atorvastatin, 36 drug interactions, 182, 186 Atrial fibrillation, warfarin and, 95Antidepressants, 148 Avapro, 103 drug interactions, 182–85Antidiabetic medications, 73–75 Baby aspirin, 93Antifungals, drug interactions, Bad cholesterol. See LDL 182, 185, 186 cholesterolAntihypertension medications, Bad fats, 112–15 Banting, Fred, 66 19–22 Bariatric surgery, 61 African-Americans and, 24 Beer. See Alcohol drug interactions, 184–85 Benazepril, 101 side effects, 20–21 Benicar, 103Anti-inflammatories, 92, 141–42. Best, Charles, 66 Beta-adrenergic receptors, 96 See also Aspirin Beta-blockers, 88, 96–100 drug interactions, 182–85Antioxidants, 125, 202 commonly used, and brandAppointments, doctor, 149–50 names, 97ARBs (angiotensin II receptor defined, 202 blockers), 19, 102–3 drug interactions, 183 commonly used, and brand frequently asked questions, names, 103 99–100 defined, 201 for post–heart attacks, 104 side effects, 21

INDEX 251 recommended guidelines, Blood vessels, 1–2 97–98 Body Mass Index (BMI), 54–55, risks and benefits, 98–99 64 side effects, 21, 98 Borderline high glucose, 67, 70Beta carotene, 128 Breathlessness, as symptom ofBetapace, 97Betaxolol, 97 heart disease, 3, 144Bile acid resins, 38, 184 Buffered aspirin, 92Binge-drinking, 126 Bupropion, 81–82Bisoprolol, 97, 183 B vitamins, 127Black, James, 96, 97 Bypass surgery, 197, 203Black tea, 122–23Blocadren, 97 aspirin and, 89–90, 91Blood chemistry tests, 189–90Blood pressure, 12–30 CABG. See Coronary artery bypass frequently asked questions, grafting surgery 22–25 Caffeine, 24, 123 high. See Hypertension Calcium, 23 lifestyle changes for, 17–18, Calcium channel-blockers, 23, 26–30 202 low (hypotension), 20–21, 23 diuretics versus, 19 measurement of, 14–15, 25 drug interactions, 185 medications for, 19–22, 96–103 side effects, 21 My Blood Pressure Log, 164–65 Calories (caloric intake), 55–59, recommended guidelines, 15–17Blood sugar (glucose), 65–77 109, 123 defined, 203 defined, 202 frequently asked questions, how much to cut, 56–58, 124 Cancers, 77, 78, 117, 118, 132 75–77 Canola oil, 34, 114 glycemic index and, 71–72 Capoten, 101 heart and, 69–70 Captopril, 101 high. See Hyperglycemia Carbohydrates, 55–59, 63, 65, 111 lifestyle changes for, 70–73 Cardiac catheterization, 6, medications for, 73–75 My Sugars Log, 174–75 195–96, 202 recommended guidelines, 68–69 Cardiac-resynchronization therapy, tests for, 67–69, 188–89Blood tests, 5, 187–90 140–41 for cholesterol, 31–32, 187–88 Cardiovascular disease, defined, for glucose, 67–68, 188–89 statins and, 37 202Blood thinners (anticoagulants), Carteolol, 97 Cartrol, 97 88–96. See also Aspirin Carvedilol, 97, 183 defined, 202 CBT (cognitive behavior therapy), drug interactions, 182, 186 148–49 Centers for Disease Control and Prevention (CDC), 42, 200, 202 flu and, 146–47

252 INDEXChannel blockers. See Calcium Coated aspirin, 92 channel-blockers Coconut oil, 113 Coenzyme Q10, 128Charts. See Forms Coffee, 24, 123Checklist, Just-After-a-Heart- Cognitive behavior therapy (CBT), Attack, 161 148–49Chest discomfort, as symptom of Colesevelam, 38 Colestipol, 38 heart disease, 3, 144. See also Commercial weight-loss programs AnginaChocolate, 93 and diets, 63Cholesterol, 30–40 Communication, with your doctor, bad. See LDL cholesterol blood tests, 31–32, 187–88 150 diabetes and, 70 Cooling down, after exercise, 46 emerging therapies, 137–38 COPD, beta-blockers and, 99 estrogen therapy and, 130 Coreg, 97 fats and, 30, 33–34, 112–15 Corgard, 97 frequently asked questions, Coronary angiograms, 6, 195–96 39–40 Coronary arteries, 1–2, 4, 30–31, garlic for, 40, 123 good. See HDL cholesterol 203 lifestyle changes for, 33–34, 40 Coronary artery bypass grafting measurement of, 31–32, 187–88 surgery (CABG), 197, 203 medications for, 34–39, 137–38, aspirin and, 89–90, 91 184 Coronary artery disease, defined, My Cholesterol Log, 166–67 nuts and, 120 203 olive oil and, 121 Coumadin (warfarin), 95–96 recommended guidelines, 32–33, 39 with aspirin, post–heart attack, as risk factor, 7 105 soy foods and, 122Cholestyramine, 38 drug interactions, 182Chronic obstructive pulmonary vitamin E and, 127 disease (COPD), beta- Counseling blockers and, 99 for depression, 148–49Cialis, 186 for quitting smoking, 83Cigarette smoking. See Smoking Cozaar, 103Circulatory system, 12–13 C-reactive protein, 141–42Clinical trials, 135–37 Creatine kinase (CK) tests, 37Clofibrate, 38–39 Crestor, 36Clonidine, 83 CT (computerized tomography)Clopidogrel, 94, 104–5 drug interactions, 182 scans, 6, 194 side effects, 94 Dairy products, 27, 110–13, 121 Danshen, 128 DASH Diet, 26–30 African-Americans and, 24 sample menu, 28–29 tips on eating, 29–30

INDEX 253Defibrillators, 139–40 Diovan, 103Denial, patient’s view of, 133–34 Diuretics, 19, 23Depression, 147–49 defined, 203 beta-blockers and, 100 drug interactions, 185 stress and, 129 side effects, 21 symptoms, 148 Doctor’s appointment, 149–50Diabetes, 66–67 Dong quai, 128 frequently asked questions, Drinking, 124–26 benefits of, in moderation, 125 75–77 blood pressure and, 18 glycemic index and, 71–72 Drug-eluting stents, 139, 196 medications for, 73–75 Drugs. See Medications; and as risk factor, 7, 69–70 strategies for controlling, 70–75 specific drugsDiagnosis. See Tests Dyslipidemia, 188. See also HighDiastolic blood pressure, 14, cholesterol 22–23 defined, 203 ECGs. See Electrocardiograms recommended guidelines, Echocardiograms, 5, 192–93, 203 Edema, 3 15–16 Ejection fraction, defined, 203Diet, 52–60, 109–24 Elderly, the blood sugar and, 70–72 age, as risk factor, 6, 7 Body Mass Index and, 54–55, aging, calorie restriction and, 64 124 caloric intake, 56–59, 109, 123, flu and, 146 weight loss and, 62–63, 65 124 Electrocardiograms (ECGs; cholesterol and, 33–34, 40 DASH, 26–30 EKGs), 5, 190, 203 fats and, 112–15 Electron-beam computerized fiber and, 118–19 fish and, 115–17 tomography (EBCT), 194 food pyramid and, 110–12 Electrophysiology tests, 194–95 frequently asked questions, Emerging therapies, 135–42 Emotional distress, 147–49 62–65, 122–24 Emphysema, beta-blockers and, 99 low-carbohydrate, 55–56, 63, 65 Enalapril, 101 low-fat, 33–34, 55–56 End-of-life preferences, 150–52 Mediterranean, 34, 121–22, Enteric-coated aspirin, 92 Ephedra, 23–24, 62 124–25 Essential hypertension, 16–17 Ornish Program, 132–33 Estrogen, 130–32 recommended guidelines, Exercise, 40–52, 59 53–55, 62–63 amount of, 45–46, 48 support system for, 59–60 benefits of, 41, 43 weight-loss strategy, 55–60, blood pressure and, 18 blood sugar and, 72–73 120–22Dietary supplements, 62, 127–28Digoxin, 185

254 INDEXExercise (continued) Fenofibrate, 38–39 cholesterol and, 34 Fiber, 26, 40, 118–19 choosing an activity, 44–45 Fibrates, 38–39, 184 frequently asked questions, Fish, 27, 34, 111, 115–17, 120 47–50 Fish-oil supplements, 116, 117 My Exercise Log, 170–73 Fitness. See Exercise patient’s view, 50–52 Flavonoids, 93, 123 recommended guidelines, Flu, 145–47 42–43, 46 Fluvastatin, 36 stress tests, 5–6, 48, 191–92 Folic acid, 127, 128 target heart rate and, 45–46, 47 Food and Drug AdministrationExtra lean, on food labels, 113 (FDA), 23–24, 60, 81Eye disease, diabetic, 75 Food labels, 112Eye drops, beta-blockers in, 99Ezetimibe, 39 fat content, 113 heart-healthy, 122Fainting, as symptom of heart sodium content, 112 disease, 3 Food pyramid, 110–12 Foot examinations, diabetes and,Family history, as risk factor, 6, 7FAQs (frequently asked questions) 75 Forms ACE inhibitors, 102–3 aspirin, 92–94 Just-After-a-Heart-Attack beta-blockers, 99–100 Checklist, 161 blood pressure, 22–25 blood sugar (glucose), 75–77 My Blood Pressure Log, cholesterol, 39–40 164–65 diet, 62–65, 122–24 exercise, 47–50 My Cholesterol Log, 166–67 smoking, 84, 86 My Exercise Log, 170–73 weight control, 62–65 My Healthy Heart Log,Fasting blood glucose, 68, 188Fat-free, on food labels, 113 162–63“Fat-free” snacks, 124 My Sugars Log, 174–75Fatigue, as symptom of heart My Weight Log, 168–69 Fosinopril, 101 disease, 3, 145 Framingham Heart Study, 6, 13Fats, 55–59, 110–15 French paradox, 124–25 Fruits and vegetables, 117–18, cholesterol and, 30, 33–34 on food labels, 113 120, 121 good versus bad, 112–15 DASH Diet and, 26–29Fat substitutes, 124 food pyramid and, 110–11Fatty acids, 34, 112–17 LDL cholesterol and, 34Fatty fish, 115–17FDA (Food and Drug Garlic, 40, 123, 128 Gemfibrozil, 38–39 Administration), 23–24, 60, Gene therapy, 141 81 Ginger, 128 Ginkgo, 128 Ginseng, 128

INDEX 255Glaucoma, 99 Heart attacks (myocardialGlitazones, 74 infarctions), 4, 204Glossary of terms, 201–6Glucose. See Blood sugar Just-After-a-Heart-AttackGlucose tests, 67–69, 188–89 Checklist, 161Glycemic index, 71–72Glycosylated hemoglobin, 69 medications for after, 103–5Goals, setting, 143–44 while exercising, 48–49Good cholesterol. See HDL Heart failure beta-blockers and, 100 cholesterol cardiac-resynchronizationGood fats, 112–15Grains, 26, 111, 118–19, 120 therapy for, 140–41Grapefruit juice, 37, 186 defined, 203–4Grape juice, 93 implantable cardiacGreen tea, 123Gum, nicotine, 81, 82 defibrillators for, 139–40 “Heart-healthy” food labels, 122Hale, Stephen, 12 Heart rateHawthorn, 128HCTZ. See Diuretics exercise and, 43HDL (high-density lipoprotein) irregular. See Irregular heartbeat target, 45–46, 47 cholesterol, 31, 32–40 Hellebore, 128 antioxidants and, 125 Hemoglobin A1c (HbA1c) level, defined, 203 diabetes and, 70 69, 189 emerging therapies, 138 Hemorrhagic stroke, 91 estrogen therapy and, 130 Herbal supplements, 62, 127–28 exercise for, 41 Heredity, 6, 7, 141 fats and, 113–14 High blood pressure. See recommended guidelines, Hypertension 32–33, 39 High blood sugar. See soy foods and, 122Health Professionals’ Follow-Up Hyperglycemia High cholesterol, 31, 32–33 Study, 110, 115, 117Healthy Heart Log, 162–63 defined, 204Heart recommended guidelines, blood pressure and, 13 32–33 blood sugar and, 69–70 as risk factor, 7 fiber and, 118–19 High-density lipoprotein. See HDL fish and, 115–17 My Healthy Heart Log, cholesterol Hip fractures, hormone therapy 162–63 smoking and, 77–78 and, 132Heart and Estrogen/Progestin Holter monitoring, 191, 204 Homocysteine, 127 Replacement Study, 131 Hormone therapy, 130–32, 204 Hydrochlorothiazide. See Diuretics Hydrogenated vegetable oils, 113–14 Hypercholesterolemia, 204. See also High cholesterol

256 INDEXHyperglycemia (high blood sugar), Insulin injections, 73–75 66–67 Insulin resistance. See Type II defined, 204 diabetes frequently asked questions, International Normalized Ratio 75–77 (INR), 95 medications for, 73–75 Inuit diet, 115 as risk factor, 7, 69–70 Irregular heartbeat, 140 strategies for controlling, 70–75 tests for, 67–69, 188–89 beta-blockers and, 96–97Hyperlipidemia, 204. See also High warfarin and, 95 Ischemic, defined, 204 cholesterol Islet cells, 76Hypertension (high blood Jogging log, 172–73 pressure), 13, 14 Just-After-a-Heart-Attack classification of, 16–17 DASH Diet for, 26–30 Checklist, 161 defined, 204 exercise for, 41 Kassirer, Jerome P., ix–x frequently asked questions, Kerlone, 97 Key strategies, 7–107 22–25 herbal remedies for, 128 blood pressure control, 12–30 lifestyle changes for, 17–18, blood sugar control, 65–77 cholesterol control, 30–40 26–30 exercise, 40–52 measurement of, 14–15, 25 medications, 88–107 medications for, 19–22, 96–103, monitoring your heart, 143–45 smoking, 77–87 184–85 weight control, 52–65 as risk factor, 7 as silent killer, 8, 13 Labels. See Food labels white coat, 25 Labetalol, 97Hypoglycemia, 73 LDL (low-density lipoprotein)Hypotension (low blood pressure), cholesterol, 31, 32–40 20–21, 23 antioxidants and, 125 defined, 204Ibuprofen, 92, 93–94 diabetes and, 70Imaging tests, 5–6, 191–94 estrogen therapy and, 130Impaired glucose tolerance, 67, 70 fats and, 113–14Implantable cardiac defibrillators lifestyle changes for, 33–34, (ICD), 139–40 40Impotence, beta-blockers and, medications for, 34–39 recommended guidelines, 98Inderal, 97 32–33, 39Indomethacin, 92 soy foods and, 122Influenza, 145–47 Lean, on food labels, 113Inhalers, nicotine, 81, 82 Lescol, 36Insoluble fiber, 118Insulin, 65–67

INDEX 257Levatol, 97 Medications, 88–107. See alsoLifestyle changes. See also Alcohol; specific medications Diet; Exercise; Smoking; for blood pressure, 19–22, Weight control 96–103 for blood pressure, 17–18, 26–30 for blood sugar, 73–75 for blood sugar, 70–73 for cholesterol, 34–39, 137–38, for cholesterol, 33–34Light (lite), on food labels, 113 184Lipid panels, 31–32, 187–88 for depression, 148Lipitor, 36 drug interactions, 181–86Liquor. See Alcohol patient’s view, 106–7Lisinopril, 101 for post–heart attack, 103–5Living wills, 152 for smoking, 81–83Logs for weight control, 60–61 My Blood Pressure Log, 164–65 your doctor and, 150 My Cholesterol Log, 166–67 Meditation, 129–30 My Exercise Log, 170–73 Mediterranean diet, 34, 121–22, My Healthy Heart Log, 162–63 124–25 My Sugars Log, 174–75 Mended Hearts, 200 My Weight Log, 168–69 Menopause, 130–32Lopressor, 97 Mercury, 117Losartan, 184–85 Meridia, 60Lotensin, 101 Metabolism, 56Lovastatin, 36 Metformin, 74Low-carbohydrate diets, 55–56, Metoprolol, 97, 183 63, 65 Mevacor, 36Low-fat, on food labels, 113 Micardis, 103Low-fat diets, 33–34, 55–56 Moexepril, 101Low-saturated fat, on food labels, Monitoring, your heart’s health, 113Low-saturated fats, 114 143–45Low-sodium, on food labels, 112 Monopril, 101 Monounsaturated fats, 34, 121Mackerel, 116, 117 MRIs (magnetic resonanceMagnesium, 23Ma huang. See Ephedra imaging), 6Margarine, 113, 114 Multivitamins, 127–28Mavik, 101 My Blood Pressure Log, 164–65Mecamylamine, 83 My Cholesterol Log, 166–67Medical power of attorney, 152 My Exercise Log, 170–73Medical studies, 135–37 My Healthy Heart Log, 162–63Medication-releasing stents, 139, My Heart Watch, 199 Myocardial infarctions. See Heart 196 attacks Myocardial ischemia, defined, 204 Myocardium, defined, 204 My Sugars Log, 174–75 My Weight Log, 168–69

258 INDEXNadolol, 97 Olestra, 124Naproxen, 92 Olive oil, 34, 114, 121–22National Cancer Institute (NCI), Omega-3 fatty acids, 34, 115–17, 200 120, 204National Cholesterol Education Oral antidiabetic medications, Program, 32 73–75National Heart, Lung, and Blood Orlistat, 60–61 Ornish, Dean (Ornish Program), Institute (NHLBI), 199National Institutes of Health 132–33 Overweight, 52–65 (NIH), 204 blood pressure guidelines, blood pressure and, 18 blood sugar and, 72 15–16 diabetes and, 67 exercise guidelines, 42, 59 frequently asked questions, Web site, 199 weight loss guidelines, 60, 62 62–65Niacin, 38 recommended guidelines,Nicotine. See SmokingNicotine gum, 81, 82 53–55, 62–63Nicotine inhalers, 81, 82 as risk factor, 7Nicotine nasal spray, 81, 82 weight-loss strategy, 55–60Nicotine patches, 81, 82, 83Nicotine-replacement therapy, Pacemakers, 141 Pain relievers, 92, 93–94. See also 81–83Nicotinic acid, 38 AspirinNitrates, 185 Palpitations, as symptom of heartNitroglycerine, 186, 204Normodyne, 97 disease, 3, 144Nortriptyline, 83 Pancreas, 65–67Nuclear scans, 193–94 Pancreas transplants, 76Nurses’ Health Study, 110, 115, Pancreatitis, alcohol and, 126 Patches, nicotine, 81, 82, 83 117, 119 Pellagra, 38Nutrition labels, 112 Penbutolol, 97 Percutaneous coronary fat content, 113 heart-healthy, 122 interventions (PCIs), 196–97, sodium content, 112 205Nuts, 27, 40, 119–20 Perindopril, 101 Physicians’ Health Study, 110,Obesity, 52–65 115, 119 blood pressure and, 18 Phytochemicals, 119 blood sugar and, 72 Pindolol, 97 classifications of, 53–55 Plaque, 30–31, 205 diabetes and, 67 Plavix (clopidogrel), 94, 104–5 medications and surgery for, drug interactions, 182 60–61 side effects, 94 weight-loss strategy, 55–60 Polyunsaturated fats, 114–15, 120, 205

INDEX 259Porphyria, alcohol and, 126 Rimonabant, 61, 83Portion control, 56–59, 109, 123, Risk factors, 6–7, 88 124 measuring and tracking, 187–90Potassium, 23, 189 Rofecoxib, 92Potato chips, 124 Roosevelt, Franklin Delano, 9Power of attorney, 152Pravachol, 36 Salicylic acid, 89Pravastatin, 35–36 Salmon, 34, 116, 117Pravastatin or Atorvastatin Salt content, on food labels, 112 Salt intake, 18, 112 Evaluation and Infection Saturated fats, 112–15, 120 Therapy (PROVE-IT), 33Pregnant women cholesterol and, 33–34, 113–14 alcohol and, 126 cutting when you cook, 114 flu and, 147 defined, 205 glucose tests and, 69 fat substitutes for, 124Prescriptions. See Medications; Seattle Angina Questionnaire, 144, and specific prescriptionsPresyncope, defined, 205 177–80Preventive Services Task Force, Secondary hypertension, 17 U.S., 128 Secondhand smoke, 77, 78Prinivil, 101 Sectral, 97Procedures. See Tests Selective cholesterol absorptionProgesterone, 130–32Propanolol, 97, 183 inhibitors, 39Proteins, 55–59 Sexual dysfunction, beta-blockersPulse, heart rate and, 47 and, 98Quality of care, xii Short-acting secretagogues, 74Questionnaire, Seattle Angina, Sibutramine, 60 Side effects 144, 177–80Quinapril, 101 ACE inhibitors, 21, 102Quit dates, 84, 85 antihypertension medications,Quitlines, 83, 200 20–21Ramipril, 101 aspirin, 90–91Randomized controlled trials, beta-blockers, 21, 98 statins, 37 defined, 205 Sildenafil, 186Red meat, 27, 113, 114, 121, 122 Silver acetate, 83Reduced fat, on food label, 113 Simvastatin, 35–36, 137–38Red wine, 122, 124–26 Smoking, 77–87Refined grains, 118–19, 121 blood pressure and, 18Relaxation therapy, 129–30 cholesterol and, 40Research, emerging therapies and, five-day plan for getting ready to 135–42 quit, 85Resources, 199–200 frequently asked questions, 84, 86 heart and, 77–78 medications for quitting, 81–83

260 INDEXSmoking (continued) resources, 200 patient’s view, 86–87 for weight control, 59–60 quitlines, 83, 200 Surgeon General, U.S., 199, 200 quitting, how to, 79–85 Surgery, 195–97. See also Bypass recommended guidelines, 78–79 surgery as risk factor, 7 for obesity, 60–61 Sweeteners, artificial, 71Snack foods, 124 Swelling, as symptom of heartSodium, 18, 112Sodium-free, on food labels, 112 disease, 3, 145Soluble fiber, 118 Symptoms, xi, 2–5, 144–45Sotalol, 97Soy foods, 40, 122 for depression, 148Spertus, John, 177 for quitting smoking, 83, 84, 86Stable angina, defined, 205 Syncope, defined, 205Stage 1 hypertension, 15, 16, 19 Systolic blood pressure, 14, 22–23Stage 2 hypertension, 15, 19, 20 defined, 206Starches, 110–11, 118–19 recommended guidelines,Statins, 35–37, 137–38 15–16 drug interactions, 184 frequently asked questions, 40 Tadalafil, 186 for post–heart attacks, 104 Target heart rate, 45–46, 47 side effects, 37 Tea, 122–23 when to take, 40 TEEs (transesophagealStents, 139, 196–97, 205Strategies for action, 7–107 echocardiograms), 192–93 blood pressure control, 12–30 Television watching, 50 blood sugar control, 65–77 Tenormin, 97 cholesterol control, 30–40 Tests, 5–6, 187–97 exercise, 40–52 medications, 88–107 for blood pressure, 14–15, 25 monitoring your heart, 143–45 for blood sugar, 67–69, 188–89 smoking, 77–87 for cholesterol, 31–32, 187–88 weight control, 52–65 Tevetan, 103Strength training, 47, 49 Thiazide diuretics. See DiureticsStress, 128–30 Thrombus, defined, 206 hypertension and, 24–25 Tight glucose control, 75–76Stress tests, 5–6, 48, 191–92 Timolol, 97, 183Stretching, 46, 47 Tobacco. See SmokingStrokes, statins and, 35 Toprol XL, 97Sulfonylureas, 74 Total cholesterol, 31, 32–33, 39Supplements, 62, 127–28 Trandolapril, 101Support system Transesophageal echocardiograms for quitting smoking, 84, 200 (TEEs), 192–93 Trans fatty acids, 34, 112–15 Treatment. See also Key strategies; and specific treatments quick guide to, 157–58

INDEX 261Triglycerides, 31–33 drug interactions, 182 defined, 206 vitamin E and, 127 fish and, 115, 116 Warm-ups, before exercise, 46 hormone therapy and, 130–31 Water pills. See Diuretics measurement of, 31–32, WebMD, 200 187–88 Weight control, 52–65. See also recommended guidelines, 32–33 Diet blood sugar and, 70–72Tuna, 116, 117 Body Mass Index and, 53–55,Twain, Mark, 78Tylenol, 92 64Type A personality, 128–29 calorie intake and, 29, 56–59,Type I diabetes, 66–67Type II diabetes, 66–67, 70, 76 109, 112 cholesterol and, 34Ultrasound tests, 192–93 frequently asked questions,Underweight, 54Univasc, 101 62–65Unsalted, on food labels, 112 My Weight Log, 168–69Unstable angina, defined, 206 obesity epidemic and, 52–53USDA (U.S. Department of support system for, 59–60 weight-loss strategy, 55–60, Agriculture), 110, 111Urge to smoke, 86 120–22 Weight gainVaccines, flu, 145–47Vasotec, 101 insulin injections and, 76–77Vegetable oils, 113–14 “rebound,” 59Vegetables. See Fruits and Weight lifting, 47, 49 Weight-loss programs and diets, 63 vegetables Weight-loss strategy, 55–60,Viagra, 186Vioxx, 92 120–22Visken, 97 Welchol, 38Vitamin B3, 38 Wellbutrin SR, 81–82Vitamin B6, 127 Western diet, 121Vitamin B12, 127 White coat hypertension, 25Vitamin E, 127, 128 Whole grains, 26, 111, 118–19,Vitamins, 127–28 120Walking, 42–43, 45, 48, 59 Wine, 122, 124–26 log for, 171 Withdrawal symptoms, 83, 84, 86 Women’s Health Initiative Study,Walnuts, 120Warfarin, 95–96 131–32 Worksheets with aspirin, post–heart attack, 105 Just-After-a-Heart-Attack Checklist, 161 My Blood Pressure Log, 164–65 My Cholesterol Log, 166–67 My Exercise Log, 170–73 My Healthy Heart Log, 162–63

262 INDEXWorksheets (continued) Zebeta, 97 My Sugars Log, 174–75 Zestril, 101 My Weight Log, 168–69 Zetia, 39 Zocor, 36Xenical, 60–61 Zocor (simvastatin), 35–36,Yoga, 129 137–38 Zyban, 81–82

About the AuthorHarlan M. Krumholz, M.D., is a professor of cardiology,epidemiology, and public health at the Yale University School ofMedicine and director of the Yale–New Haven Hospital Center forOutcomes Research and Evaluation. Author of more than 250journal articles, Dr. Krumholz serves on numerous cardiovascularcare committees for national organizations, including the AmericanHeart Association and the American College of Cardiology.Don’t miss the next book by your favorite author. Sign up now forAuthorTracker by visiting www.AuthorTracker.com.

CreditsDesigned by Fritz Metsch

CopyrightTHE EXPERT GUIDE TO BEATING HEART DISEASE. Copyright © 2005Harlan M. Krumholz, M.D. All rights reserved. Forewordcopyright © 2005 Jerome P. Kassirer, M.D.All rights reservedunder International and Pan-American Copyright Conventions. Bypayment of the required fees, you have been granted the non-exclusive, non-transferable right to access and read the text of thise-book on-screen. No part of this text may be reproduced,transmitted, down-loaded, decompiled, reverse engineered, orstored in or introduced into any information storage and retrievalsystem, in any form or by any means, whether electronic ormechanical, now known or hereinafter invented, without theexpress written permission of PerfectBound™.PerfectBound™ and the PerfectBound™ logo are trademarks ofHarperCollins Publishers, Inc.Adobe Acrobat eBook Reader January 2005 ISBN 0-06-077194-1Library of Congress Cataloging-in-Publication DataKrumholz, Harlan M.The expert guide to beating heart disease : what youabsolutely must know / Harlan M. Krumholz.p. cm.Includes bibliographical references and index.

About the PublisherAustraliaHarperCollins Publishers (Australia) Pty. Ltd.25 Ryde Road (PO Box 321)Pymble, NSW 2073, Australiahttp://www.perfectbound.com.auCanadaHarperCollins Publishers Ltd.55 Avenue Road, Suite 2900Toronto, ON, M5R, 3L2, Canadahttp://www.perfectbound.caNew ZealandHarperCollinsPublishers (New Zealand) LimitedP.O. Box 1Auckland, New Zealandhttp://www.harpercollins.co.nzUnited KingdomHarperCollins Publishers Ltd.77-85 Fulham Palace RoadLondon, W6 8JB, UKhttp://www.uk.perfectbound.comUnited StatesHarperCollins Publishers Inc.10 East 53rd StreetNew York, NY 10022http://www.perfectbound.com